The effects of four, commercial ceruminolytic agents on the middle ear.
Four, commercially available ceruminolytic agents and physiological saline were screened for ototoxic and inflammatory reactions on the middle ear mucosae of guinea pigs (n = 38) and dogs (n = 24). Each solution was injected transtympanically in anesthetized animals. The effects were assessed by brain stem auditory evoked response (BAER) tests to evaluate hearing function and by histological examination of the middle ear structures. Varying degrees of hearing loss and inflammation were observed in some guinea pigs and dogs treated with solutions A, C, and D, whereas no abnormal finding was associated with solution B or saline.
Mansfield
P D
PD
Department of Small Animal Surgery, College of Veterinary Medicine, Auburn University, Alabama 36849-5523, USA.
Steiss
J E
JE
Boosinger
T R
TR
Marshall
A E
AE
D000818:Animals; D000077463:Carbamide Peroxide; D002571:Cerumen / Q000187:drug effects* / Q000502:physiology; D004143:Dioctyl Sulfosuccinic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004432:Ear, Middle / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016057:Evoked Potentials, Auditory, Brain Stem; D005260:Female; D005990:Glycerol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006168:Guinea Pigs; D006314:Hearing Loss, Conductive / Q000139:chemically induced / Q000503:physiopathology / Q000662:veterinary; D007267:Injections / Q000379:methods / Q000662:veterinary; D008297:Male; D010033:Otitis Media / Q000188:drug therapy / Q000662:veterinary*; D010545:Peroxides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019946:Propylene Glycol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation; D013185:Squalene / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013501:Surface-Active Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014508:Urea / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000159:Vestibulocochlear Nerve / Q000502:physiology
D004338:Drug Combinations; D004983:Ethanolamines; D010545:Peroxides; D013501:Surface-Active Agents; D004143:Dioctyl Sulfosuccinic Acid; D000077463:Carbamide Peroxide; D019946:Propylene Glycol; D013185:Squalene; D014508:Urea; D005990:Glycerol